Table 2.
Changes in Lin-DR-CD11b+ cells during chemotherapy in patients with baseline values > median
| Number | Stage | Baseline Lin-DR-CD11b+ | Post therapy Lin-DR-CD11b+ | Change (%) | Radiological response |
|---|---|---|---|---|---|
| 1 | III | 2.58 | 18.16 | +604 | SD (0 %) |
| 2 | IV | 3.65 | 4.12 | +13 | PD |
| 3 | III | 2.25 | 3.33 | +48 | SD (0 %) |
| 4 | IV | 2.54 | 1.59 | −37 | SD (−11 %) |
| 5 | IV | 2.0 | 1.08 | −46 | SD (0 %) |
| 6 | IV | 2.69 | 3.64 | +35 | PD |
| 7 | IV | 2.23 | 4.12 | +85 | PD |
| 8 | IV | 2.96 | 0.94 | −68 | PR |
| 9 | III | 1.86 | 2.02 | +9 | SD (0 %) |
Cryopreserved PBMCs obtained from patients with advanced pancreatic cancer before (baseline) and after treatment with gemcitabine and capecitabine chemotherapy were immunostained for HLA-DR-APC-Cy7, Lin1 (CD3,14,16,19,20,56)-FITC and CD11b-PECy7 and ViViD to discriminate live and dead cells. Following immunostaining, cells were analyzed using a MACSQuant flow cytometer with MACSQuantify software. Numbers represent % change in the Lin-DR-CD11b+ cells only in those patients with baseline Lin-DR-CD11b+ greater than the median. There was no consistent reduction in Lin-DR-CD11b+ % secondary to gemcitabine and capecitabine chemotherapy. SD = stable disease and PR = partial response and PD = progressive disease